Eversept Partners LP Makes New $6.32 Million Investment in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Share on StockTwits

Eversept Partners LP bought a new position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 87,140 shares of the biopharmaceutical company’s stock, valued at approximately $6,323,000. Alnylam Pharmaceuticals comprises about 1.8% of Eversept Partners LP’s holdings, making the stock its 16th biggest position. Eversept Partners LP owned approximately 0.08% of Alnylam Pharmaceuticals as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. Capital Investment Advisory Services LLC bought a new stake in shares of Alnylam Pharmaceuticals in the second quarter worth $25,000. US Bancorp DE boosted its position in Alnylam Pharmaceuticals by 70.2% during the second quarter. US Bancorp DE now owns 628 shares of the biopharmaceutical company’s stock valued at $46,000 after acquiring an additional 259 shares during the last quarter. Price Wealth Management Inc. bought a new stake in Alnylam Pharmaceuticals during the second quarter valued at $46,000. Northwestern Mutual Wealth Management Co. boosted its position in Alnylam Pharmaceuticals by 268.9% during the first quarter. Northwestern Mutual Wealth Management Co. now owns 701 shares of the biopharmaceutical company’s stock valued at $66,000 after acquiring an additional 511 shares during the last quarter. Finally, Tower Research Capital LLC TRC boosted its position in Alnylam Pharmaceuticals by 444.7% during the second quarter. Tower Research Capital LLC TRC now owns 828 shares of the biopharmaceutical company’s stock valued at $60,000 after acquiring an additional 676 shares during the last quarter. 94.26% of the stock is currently owned by institutional investors.

Shares of NASDAQ ALNY traded up $1.71 during trading on Friday, hitting $84.88. 59,459 shares of the company traded hands, compared to its average volume of 668,636. The business’s fifty day moving average is $79.70 and its 200 day moving average is $78.88. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $60.27 and a fifty-two week high of $99.73. The firm has a market capitalization of $9.30 billion, a price-to-earnings ratio of -11.21 and a beta of 2.35. The company has a debt-to-equity ratio of 0.17, a quick ratio of 6.16 and a current ratio of 6.28.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($2.02) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($2.06) by $0.04. Alnylam Pharmaceuticals had a negative net margin of 848.70% and a negative return on equity of 56.42%. The company had revenue of $38.20 million for the quarter, compared to analyst estimates of $42.24 million. During the same quarter in the prior year, the business posted ($1.61) EPS. The firm’s revenue was up 27.8% compared to the same quarter last year. On average, analysts predict that Alnylam Pharmaceuticals, Inc. will post -8.21 EPS for the current year.

ALNY has been the topic of a number of research analyst reports. Goldman Sachs Group reaffirmed a “neutral” rating and set a $80.00 price target on shares of Alnylam Pharmaceuticals in a research report on Thursday, May 23rd. Morgan Stanley cut their price target on shares of Alnylam Pharmaceuticals from $126.00 to $124.00 and set an “overweight” rating on the stock in a research report on Wednesday, August 7th. ValuEngine raised shares of Alnylam Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Thursday, August 1st. BidaskClub raised shares of Alnylam Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Friday. Finally, UBS Group upped their price objective on shares of Alnylam Pharmaceuticals from $95.00 to $96.00 and gave the company a “neutral” rating in a report on Wednesday, September 4th. Five research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company. Alnylam Pharmaceuticals currently has a consensus rating of “Buy” and an average price target of $116.13.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics. The company's pipeline of investigational RNAi therapeutics focus on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system/ocular diseases.

Featured Story: Earnings Reports

Institutional Ownership by Quarter for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Eversept Partners LP Has $15.71 Million Stake in Ascendis Pharma A/S
Eversept Partners LP Has $15.71 Million Stake in Ascendis Pharma A/S
Amarin Co. plc  Stock Holdings Lessened by Eversept Partners LP
Amarin Co. plc Stock Holdings Lessened by Eversept Partners LP
Eversept Partners LP Cuts Stock Holdings in Sanofi SA
Eversept Partners LP Cuts Stock Holdings in Sanofi SA
Eversept Partners LP Makes New $6.32 Million Investment in Alnylam Pharmaceuticals, Inc.
Eversept Partners LP Makes New $6.32 Million Investment in Alnylam Pharmaceuticals, Inc.
Eversept Partners LP Buys 8,930 Shares of argenx SE –
Eversept Partners LP Buys 8,930 Shares of argenx SE –
Eversept Partners LP Has $20.76 Million Holdings in Danaher Co.
Eversept Partners LP Has $20.76 Million Holdings in Danaher Co.


© 2006-2019 Ticker Report